Pacira BioSciences, Inc.
PCRX
$21.84
-$0.85-3.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 107.07% | 123.63% | -300.43% | -247.19% | -337.30% |
| Total Depreciation and Amortization | 15.53% | 12.36% | 21.26% | 9.58% | 4.25% |
| Total Amortization of Deferred Charges | -6.98% | 7.38% | 19.33% | 19.11% | -14.03% |
| Total Other Non-Cash Items | -59.09% | -55.10% | 198.65% | 261.10% | 175.48% |
| Change in Net Operating Assets | -244.80% | -610.71% | -157.42% | 18.06% | 75.76% |
| Cash from Operations | -19.75% | -30.61% | -30.79% | -4.81% | 22.46% |
| Capital Expenditure | -44.16% | -67.05% | -81.48% | -43.00% | 29.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 281.05% | 277.08% | 206.23% | -930.92% | -178.36% |
| Cash from Investing | 219.46% | 207.04% | 40.12% | -2,138.14% | -207.40% |
| Total Debt Issued | -64.87% | -64.87% | -100.00% | -- | 92.24% |
| Total Debt Repaid | -50.70% | -49.66% | 94.83% | -481.75% | 36.16% |
| Issuance of Common Stock | 43.73% | 0.48% | -0.99% | -47.97% | -51.62% |
| Repurchase of Common Stock | -503.92% | -313.91% | -118.20% | -23,234.55% | -23,948.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.94% | 93.89% | 100.00% | -- | -421.61% |
| Cash from Financing | -2,228.82% | -1,924.11% | -782.06% | 153.80% | 109.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.75% | -166.99% | -66.66% | -32.96% | 151.18% |